Скачать или смотреть Sorfequiline: Revolutionizing Tuberculosis Treatment with Shorter, Safer Therapy | TB Breakthrough

Discover how sorfequiline, combined with pretomanid and linezolid (SPaL), is set to transform tuberculosis (TB) treatment. This groundbreaking Phase 2 clinical trial data reveals sorfequiline's superior anti-TB activity compared to standard HRZE therapy, with a comparable safety profile. Learn how this innovative regimen could shorten treatment duration, address drug resistance, and improve patient outcomes. Ideal for healthcare professionals, researchers, and anyone interested in the latest advancements in TB pharmacotherapy.
Key Highlights:
Sorfequiline outperforms current standard TB treatments
Potential to reduce treatment duration to as little as 1 month
Addresses emerging bedaquiline-resistant strains
Phase 3 trials planned for 2026
Keywords: Sorfequiline, Tuberculosis Treatment, TB Therapy, SPaL Regimen, Drug-Resistant TB, TB Alliance, Phase 2 Clinical Trial, Shortened TB Treatment, Bedaquiline Resistance, TB Pharmacotherapy